Navigation Links
Velcura Therapeutics, Inc. Reports Successful Phase 1 Clinical Trial of Novel Bone Disease Therapy
Date:5/12/2008

ANN ARBOR, Mich., May 12 /PRNewswire/ -- Velcura Therapeutics, Inc. announced the successful completion of a first-in-man clinical trial for its lead compound, VEL-0230, which the company is investigating as a treatment for Rheumatoid Arthritis (RA) and other bone diseases. In extensive preclinical studies, VEL-0230 proved to be a powerful anti-inflammatory agent that also stimulates bone formation and inhibits bone loss. Taken together, these characteristics strongly suggest this drug may be an important therapy for RA patients.

"The successful completion of the first studies in healthy human volunteers is an important milestone in developing VEL-0230 as a therapy," said Michael W. Long, PhD, President and Chief Executive Officer of Velcura. "While we are still analyzing and tabulating the data, our preliminary conclusions are that the drug is safe and well-tolerated over a range of doses."

"During this initial safety study in humans, the drug caused a rapid (within 15 minutes) and marked (80%) reduction in CTx levels, a biomarker of bone resorption. Our next step is to evaluate the drug for efficacy in RA patients," said Dr. Long who added, "We plan to move into multiple clinical studies as rapidly as possible."

VEL-0230 is being studied as an orally available molecule that promotes bone formation, inhibits bone loss and reduces inflammation. If successful in RA patients Velcura Therapeutics plans to study it as a treatment for other bone disorders, such as bone loss related to multiple myeloma, bone metastases, and osteoporosis.

About Velcura Therapeutics, Inc.

Velcura Therapeutics, Inc. is an early stage biotechnology company headquartered in Ann Arbor, Michigan. Velcura's research focus is to understand human bone disease and to discover novel therapeutics that restore bone health. Velcura develops highly differentiated therapies for bone disease; specifically, therapies that restore the balance between bone building and bone loss activities in a single molecule. Velcura uses its patented platform technologies to discover and optimize these compounds. More information is at http://www.velcura.com.
Available Topic Expert(s): For information on the listed expert(s), click appropriate link. Michael W. Long, Ph.D. http://profnet.prnewswire.com/Subscriber/ExpertProfile.aspx?ei=49215


'/>"/>
SOURCE Velcura Therapeutics Inc.
Copyright©2008 PR Newswire.
All rights reserved

Related medicine technology :

1. NIST Awards $2 Million to Velcura Therapeutics, Inc. for Innovative Technology R&D - Dual-Action Therapies for Bone Disease
2. Velcura Therapeutics, Inc. Reports Positive Pre-IND Meeting With FDA and Plans Early Clinical Trials for New Drug to Treat Multiple Myeloma Bone Disease
3. European Regulatory Agency Accepts Cell Therapeutics, Inc.s Marketing Authorization Application for XYOTAX(TM) for Lung Cancer for Review
4. Cell Therapeutics, Inc. (CTI) Announces Enrollment Complete in Phase III EXTEND (PIX301) Clinical Trial of Pixantrone in Patients With Second or Greater Relapse of Diffuse Large B Cell NHL
5. Dynamis Therapeutics, Inc. Discovers RAGE Inhibitor
6. Cell Therapeutics, Inc. (CTI) Submits European Marketing Authorization Application for XYOTAX(TM)
7. William R. Ringo Joins Hyperion Therapeutics, Inc. Board of Directors as Chairman
8. Ocera Therapeutics, Inc. Completes Enrollment in FHAST1, a Pivotal Phase 3 Clinical Trial in Fistulizing Crohns Disease
9. Cell Therapeutics, Inc. (CTI) Supports Panel Discussion on Women and Lung Cancer on Capitol Hill
10. Cell Therapeutics, Inc. (CTI) Sponsors Panel Discussion on Women and Lung Cancer on Capitol Hill
11. Cell Therapeutics, Inc. (CTI) Launches Phase III Study for Pixantrone in Relapsed Indolent Non-Hodgkins Lymphoma (NHL)
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/5/2016)... , Feb. 5, 2016  Henry Schein, Inc. (NASDAQ: ... products and services to office-based dental, animal health and ... an agreement to acquire a majority ownership interest in ... equipment in Brazil . ... Blumenau, Brazil, Dental Cremer is the dental distribution business of ...
(Date:2/5/2016)... 4, 2016 France , ... , UK, and Israel ). It includes a 10-year ... 3 GD, segmented by age and sex in these markets. GD epidemiology ... Report is in-depth, high quality, transparent and market-driven, providing expert analysis of ... Germany , Italy , ...
(Date:2/4/2016)... For hospitals considering enrollment in the Federal ... the program, the Health Resources and Services Administration,s (HRSA) ... Mega-Guidance , could have significant impact on plans and ... 2016. Essential Insights , Daniel Neal, ... the Mega-Guidance,s key proposed changes, including a new requirement ...
Breaking Medicine Technology:
(Date:2/5/2016)... & Salt Lake City, UT (PRWEB) , ... February 05, 2016 ... ... of Activz Whole-Food Nutrition , announced that the much-anticipated feature with author Jahnavi ... New Really Cool Humans Amateur TV Network. , Each week, on his weekly Whole-Food ...
(Date:2/5/2016)... (PRWEB) , ... February 05, 2016 , ... Looking for ... may be at the tips of your toes. Foot massage, whether administered by a ... pure comfort and relaxation. The American Board of Multiple Specialties in Podiatry ...
(Date:2/5/2016)... ... February 05, 2016 , ... In ... across the country gathered at the La Valencia Hotel in San Diego, California ... Chicago was named the year’s most outstanding franchise, walking away with the coveted ...
(Date:2/5/2016)... ... February 05, 2016 , ... Pivot Point Consulting, a leading ... Software & Services for HIT Implementation Support & Staffing report with an outstanding ... performance by healthcare executives, managers and clinicians representing over 4,500 hospitals and 2,500 ...
(Date:2/5/2016)... , ... February 05, 2016 , ... Colorize ... on one drop zone to the next using Colorize's dynamic moving camera. Colorize is ... This package includes a 3D slideshow environment with 1 to 5 focus points per ...
Breaking Medicine News(10 mins):